Lexington Biosciences Inc. (LXGTF)

[Thundercleese]

Yeah, i would agree with all you say but I would say more strongly that, barring some hugely unforeseen hiccup, HeartSentry will see commercialization this year in 2018. LXGTF has scrupulously stuck to their development timeline thus far. With the IRB happening here in the first quarter, that gives plenty of time for the average time of 6 months for clinical trials for cardiovascular devices in the FDA 410K Fast track to market. This is noninvasive technology and the pretrials showed strong correlation to predicate endothelial measurement devices, so this should be a shoe-in, barring some crazy lightning bolt from the sky type disruptive event.